



## NSC RESEARCH CURRENTLY ENROLLING TRIALS

5400 Laurel Springs Parkway Suite 1402 Johns Creek, GA 30024

1100 Northside Forsyth Dr Suite 345 Cumming GA 30041

Phone 678-507-0838 Fax 470-695-7565

Director - Narendra Singh, MD, FRCPC, FCCS, FACC, FAHA

Research Administrator- Crystal Richards

Research Coordinators: Julianna Zabala CCMA CCRC, Charlotte Mall, BS CCRC, Katherine Byrne MA CRC

### HEART FAILURE

- EASi-HF PRESERVED** → Vicadrostal and empagliflozin compared with placebo and empagliflozin tablets in participants with heart failure and preserved ejection fraction (EF >40%) – *testing an oral aldosterone synthetase inhibitor to reduce death and hospitalization for heart failure*
- EASi-HF REDUCED** → Vicadrostal and empagliflozin compared with placebo and empagliflozin tablets in participants with heart failure and reduced ejection fraction (EF >40%) – *testing an aldosterone synthetase inhibitor to reduce death and hospitalization for heart failure*
- HF-POLARIS** → Amycretin compared to placebo injections in patients with heart failure and preserved ejection fraction (EF>40%) as well as being overweight BMI > 27 or obese BMI > 30 – *testing if a weight loss drug with GLP-1 like properties can improve quality of life, exercise tolerance and reduce hospitalization rates for heart failure*

### ATRIAL FIBRILLATION

- LILAC** → Abelaclimab vs placebo injections in patients with atrial fibrillation normally unsuitable for anticoagulation therapy – *testing if a factor XI inhibitor can reduce the risk of strokes while minimizing bleeding risk*
- ROXI-ATLAS** → Regn7508 and Regn9933 vs apixaban in patients with Atrial Fibrillation – *testing the bleeding safety profile of these two Factor XI inhibitors injections compared to oral apixaban*
- ROXI-EVERST** → REGN7508 vs apixaban in patients with Atrial Fibrillation - *testing this Factor XI inhibitor injection compared to oral apixaban to reduce the risk of stroke or systemic embolization*

### OVERWEIGHT and OBESITY

- MARITIME-SWITCH** → Switching from a GLP-1 RA semaglutide or tirzepatide to Maridebart Cafraglutide in NON-diabetic adult participants with obesity BMI>30 or overweight BMI>27 who have stabilized their weight loss on full dose – *testing if the switch to the new injectable agent can cause additional weight loss*

